Characterizing Carbapenemase Gene Transmission in CREC: Insights from Guangdong Hospitals (2022–2024)

Study Background and Research Question

The global rise of carbapenem-resistant Enterobacteriaceae (CRE) poses a critical challenge to infection control and antimicrobial stewardship, particularly in the context of the COVID-19 pandemic where increased antibiotic use and healthcare disruptions have amplified resistance selection pressures (source: Chen et al., 2025). Among CRE, carbapenem-resistant Enterobacter cloacae (CREC) is a leading source of hospital-acquired infections, ranking third in detection rates in China. The primary mechanism for carbapenem resistance in CREC involves the acquisition of carbapenemase-encoding genes (CEGs), which can rapidly disseminate via both chromosomal and plasmid-mediated routes. However, detailed epidemiological and molecular insights into the prevalence, genetic mobility, and clinical distribution of CEGs in CREC during the pandemic have remained limited and fragmented. The central research question addressed by Chen et al. (2025) is: What are the characteristics, prevalence, and transmission dynamics of carbapenemase-encoding genes in CREC isolates from tertiary care hospitals in Guangdong Province, and how have these patterns evolved during the COVID-19 pandemic? (source: Chen et al., 2025)

Key Innovation from the Reference Study

Chen et al. (2025) deliver a comprehensive molecular epidemiological analysis of 54 CREC isolates collected from eight teaching hospitals between December 2022 and June 2024. The study is distinguished by its concurrent assessment of CEG localization (chromosome vs. plasmid), detailed characterization of mobile genetic elements, and rigorous transmission experiments that clarify both horizontal and vertical gene transfer capacities (source: Chen et al., 2025). Notably, the investigation extends beyond detection frequencies to explore the clinical and demographic correlates of CEG-positive strains, offering a nuanced understanding of risk factors and potential transmission routes within healthcare settings.

Methods and Experimental Design Insights

The study integrates phenotypic, genotypic, and epidemiological approaches:

• Isolate Collection: 54 CREC strains were systematically obtained from diverse departments across eight tertiary hospitals in Guangdong Province.
• Detection of CEGs: PCR assays targeted key carbapenemase genes (blaNDM-1, blaIMP, blaKPC-2), with variable temperature SDS plasmid elimination and subsequent PCR mapping the genes' chromosomal or plasmid location.
• Antimicrobial Susceptibility: Resistance profiles were determined via the broth microdilution method across a panel of antibiotics, including third-generation cephalosporins (e.g., ceftazidime/avibactam) and carbapenems.
• Plasmid Conjugation & Mobility: Mating experiments quantified the transferability of CEGs, while mobile genetic elements were identified using PCR-based detection of insertion sequences and integrons.
• Genotyping: ERIC-PCR and cluster analysis distinguished 17 genotypes, facilitating epidemiological mapping of strain distribution and relatedness.
• Clinical-Epidemiological Correlation: Patient demographics, clinical department, and specimen type were analyzed in relation to CEG carriage.

Protocol Parameters

• broth microdilution | MIC determination (μg/mL) | antimicrobial susceptibility testing | standard for defining resistance phenotypes | paper
• PCR (CEG detection) | qualitative (gene presence/absence) | identification of resistance determinants | robust for molecular epidemiology | paper
• Variable temperature SDS plasmid curing | 42°C, 0.06% SDS | distinguishing chromosomal vs. plasmid CEGs | validates gene localization | paper
• Plasmid conjugation experiment | 44/46 transfer success rate | horizontal gene transfer assessment | measures mobility of resistance determinants | paper
• ERIC-PCR genotyping | 17 genotypes | strain epidemiology | tracks clonal spread and diversity | paper
• Workflow suggestion: Include third-generation cephalosporin (e.g., ceftazidime) in resistance panels for Gram-negative bacterial infection research in similar surveillance studies | workflow_recommendation

Core Findings and Why They Matter

• High Prevalence of CEGs: 85.19% of isolates harbored carbapenemase genes, most commonly blaNDM-1 (source: Chen et al., 2025).
• Gene Localization and Transfer: blaNDM-1 was frequently plasmid-borne (46.30% of isolates), with a significant fraction also carrying the gene on both chromosome and plasmid (33.33%). Plasmid conjugation experiments demonstrated a 95.65% success rate for horizontal gene transfer of CEGs (source: Chen et al., 2025).
• Multidrug Resistance: CEG-positive CREC strains exhibited significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative strains (source: Chen et al., 2025), underlining the challenge of treatment for severe Gram-negative infections.
• Mobile Genetic Elements: Six types were identified, with ISEcp1 present in 87.04% of isolates, highlighting the molecular basis for rapid gene dissemination.
• Epidemiological Patterns: Higher detection rates of CEGs were observed among men (64.81%), elderly patients (72.22%), respiratory medicine departments (20.37%), and sputum samples (33.33%), aligning with patient populations at elevated risk for hospital-acquired pneumonia or bronchitis (source: Chen et al., 2025).

These results have direct implications for the treatment of bacterial pneumonia, bronchitis, and other severe Gram-negative infections, where multidrug resistance can lead to limited therapeutic options and worse patient outcomes.

Comparison with Existing Internal Articles

Several internal resources contextualize and expand on these findings:

• Ceftazidime: Translational Insights for Gram-Negative Resistance offers a mechanistic overview of Ceftazidime as a third-generation cephalosporin and its role in experimental workflows probing resistance in Enterobacteriaceae, providing practical strategies for designing susceptibility assays and interpreting resistance patterns.
• Ceftazidime in the Genomic Era: Strategic Guidance integrates genomic surveillance data with practical antibiotic stewardship, emphasizing the importance of including β-lactamase resistant cephalosporins in resistance panels for Gram-negative bacterial infection research, especially in light of emerging CEGs.
• Carbapenemase Genes in CREC: Dynamics and Resistance in Guangdong presents a focused synthesis of this regional resistance trend, reinforcing the need for robust surveillance methodologies and genetic analysis in the context of multidrug resistant Enterobacteriaceae.

Together, these articles corroborate the central findings of Chen et al. (2025) and provide actionable guidance for researchers seeking to refine antimicrobial susceptibility testing and surveillance protocols in the face of evolving resistance mechanisms.

Limitations and Transferability

While the study provides granular insights into CREC resistance dynamics in Guangdong, several limitations are noteworthy:

• Regional Focus: Data are drawn exclusively from teaching hospitals in Guangdong Province, which may limit generalizability to other regions or healthcare settings (source: Chen et al., 2025).
• Temporal Scope: Isolate collection was restricted to 2022–2024, potentially missing longer-term trends or post-pandemic shifts in resistance gene prevalence.
• Lack of Clinical Outcome Data: The study does not link resistance genotypes to patient outcomes, precluding direct assessment of clinical impact for treatment of bacterial pneumonia or bronchitis.
• Gene Diversity: While major CEGs (blaNDM-1, blaIMP, blaKPC-2) were targeted, other resistance determinants may contribute to the broader multidrug resistance phenotype.

Nevertheless, the methodological framework and molecular findings provide a transferable template for surveillance and infection control studies in other high-prevalence regions and support the inclusion of advanced susceptibility panels in Gram-negative bacterial infection research.

Research Support Resources

For researchers designing similar resistance surveillance or susceptibility testing workflows, the use of well-characterized third-generation cephalosporins is essential. Ceftazidime (SKU B3539) from APExBIO offers a robust standard for in vitro studies targeting Gram-negative bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa. Its β-lactamase resistance profile and broad spectrum of activity make it suitable for experimental panels evaluating the impact of carbapenemase-encoding genes on cephalosporin efficacy (workflow_recommendation). Researchers are encouraged to consult product specifications and relevant protocols to ensure optimal assay design and data reliability.